- Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
- Panbela Announces Poster Presentation at American Association for Cancer Research:
- Panbela Announces Transfer to OTCQB Market
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
More ▼
Key statistics
On Thursday, Panbela Therapeutics Inc (PBLA:QBB) closed at 0.38, 8.57% above its 52-week low of 0.35, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.40 |
---|---|
High | 0.45 |
Low | 0.3601 |
Bid | -- |
Offer | -- |
Previous close | 0.45 |
Average volume | 56.17k |
---|---|
Shares outstanding | 4.85m |
Free float | 4.85m |
P/E (TTM) | -- |
Market cap | 2.18m USD |
EPS (TTM) | -20.38 USD |
Data delayed at least 15 minutes, as of May 23 2024 20:59 BST.
More ▼